Will comparative effectiveness research finally succeed?
- PMID: 23091431
- PMCID: PMC3474453
Item in Clipboard
Will comparative effectiveness research finally succeed?
Biotechnol Healthc.
2012 Fall.
Abstract
Autonomy, innovation, and drug access may be at stake along with personalized medicine. Can all stakeholders be satisfied and should cost be a factor?
Figures
Erwin A. Blackstone, PhD
Joseph P. Fuhr Jr., PhD
Danielle Ziernicki, PharmD
Similar articles
-
Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety.Biotechnol Healthc. 2012 Spring;9(1):24-7. Biotechnol Healthc. 2012. PMID: 22606078 Free PMC article.
-
Personalized medicine and comparative effectiveness research in an era of fixed budgets.EPMA J. 2010 Dec;1(4):633-40. doi: 10.1007/s13167-010-0058-6. Epub 2010 Dec 8. EPMA J. 2010. PMID: 23199118 Free PMC article.
-
Oncotyrol--Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research.Z Evid Fortbild Qual Gesundhwes. 2015;109(4-5):330-40. doi: 10.1016/j.zefq.2015.06.012. Epub 2015 Jul 28. Z Evid Fortbild Qual Gesundhwes. 2015. PMID: 26354133
-
Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond.J Clin Oncol. 2012 Dec 1;30(34):4233-42. doi: 10.1200/JCO.2012.42.6114. Epub 2012 Oct 15. J Clin Oncol. 2012. PMID: 23071236 Free PMC article. Review.
-
Turning the tide against cancer through sustained medical innovation: the pathway to progress.Clin Cancer Res. 2014 Mar 1;20(5):1081-6. doi: 10.1158/1078-0432.CCR-13-3430. Epub 2014 Feb 12. Clin Cancer Res. 2014. PMID: 24523437 Review.
Cited by
-
The landscape of comparative effectiveness research in rheumatology.Nat Rev Rheumatol. 2014 Jan;10(1):57-62. doi: 10.1038/nrrheum.2013.140. Epub 2013 Sep 24. Nat Rev Rheumatol. 2014. PMID: 24061502
-
Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies: A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges.Front Med (Lausanne). 2020 Oct 16;7:582634. doi: 10.3389/fmed.2020.582634. eCollection 2020. Front Med (Lausanne). 2020. PMID: 33178721 Free PMC article. Review.
References
-
- Blackstone EA, Fuhr JP., Jr Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals. Future Med Chem. 2010;2:1641–1649. - PubMed
-
- Carrier E, Pham HH, Rich E. Comparative effectiveness research and innovation: policy options to foster medical advances. Oct, 2010. National Institute for Health Care Reform policy analysis no. 3. http://bit.ly/OHPP9P. Accessed July 16, 2012.
-
- CEVR (Center for the Evaluation of Value and Risk in Health) Cost-Effectiveness Analysis Registry Web site. http://bit.ly/LtBySG. Accessed Aug. 14, 2012.
-
- Chassin MR, Brook RH, Park RE, et al. Variations in the use of medical and surgical services by the Medicare population. N Engl J Med. 1986;314:285–290. - PubMed
LinkOut - more resources
Full Text Sources